Literature DB >> 28205153

Sociodemographic Disparities in Cure-Intended Treatment in Localized Prostate Cancer.

Jude K A des Bordes1, David S Lopez2,3, Michael D Swartz4, Robert J Volk5.   

Abstract

PURPOSE: Disparities in prostate cancer (PCa) morbidity and mortality occur across various populations. We investigated the sociodemographic correlates of treatment and disparities in the application of cure-intended (i.e., radical prostatectomy [RP], radiation therapy [RT]) treatment strategies in localized PCa among Texas residents diagnosed with PCa.
METHODS: We analyzed data from the Texas Cancer Registry on men diagnosed with stage T1 or T2 PCa between 2004 and 2009. Multinomial logistic regression analysis was used to explore independent associations between cure-intended treatment modalities and sociodemographic characteristics (age, race/ethnicity, socioeconomic status [SES], and geographic location (rural versus urban)) using patients who did not receive definitive treatment as comparison group.
RESULTS: Of 46,971 patients with available treatment data, age-adjusted treatment rates were 39.1% RP, 30.7% RT, and 30.2% for all other non-curative modalities. Compared to patients under 60 years, those ≥60 were less likely to receive RP, patients between 60 and 80 years were more likely to undergo RT, while those 80 years or older were less likely. Non-Hispanic blacks (OR =0.55, 95% CI, 0.50-0.59) and Hispanics (OR = 0.68, 95%CI, 0.62-0.74) were less likely to receive RP compared with whites. Hispanics were significantly less likely to receive RT (OR = 0.78, 95%CI, 0.72-0.85) than blacks and whites. People of low SES were 35% (OR = 0.65, 95%CI, 0.60-0.69) and 15% (OR = 0.85, 95%CI, 0.79-0.90) less likely to receive RP and RT, respectively, compared with those of high SES. Rural-urban status was not associated with cure-intended treatment.
CONCLUSION: Potential sociodemographic disparities exist in the application of cure-intended treatment in localized prostate cancer in Texas particularly in race/ethnicity and SES.

Entities:  

Keywords:  Demographic factors; Prostate cancer; Treatment disparities; Treatment modalities

Mesh:

Year:  2017        PMID: 28205153     DOI: 10.1007/s40615-017-0348-y

Source DB:  PubMed          Journal:  J Racial Ethn Health Disparities        ISSN: 2196-8837


  19 in total

Review 1.  Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does the choice of area-based measure and geographic level matter?: the Public Health Disparities Geocoding Project.

Authors:  Nancy Krieger; Jarvis T Chen; Pamela D Waterman; Mah-Jabeen Soobader; S V Subramanian; Rosa Carson
Journal:  Am J Epidemiol       Date:  2002-09-01       Impact factor: 4.897

2.  Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.

Authors:  Vickie L Shavers; Martin L Brown; Arnold L Potosky; Carrie N Klabunde; W W Davis; Judd W Moul; Angela Fahey
Journal:  J Gen Intern Med       Date:  2004-02       Impact factor: 5.128

3.  Racial/ethnic disparities in the treatment of localized/regional prostate cancer.

Authors:  Willie Underwood; Sonya De Monner; Peter Ubel; Angela Fagerlin; Martin G Sanda; John T Wei
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

4.  Racial disparities in cancer therapy: did the gap narrow between 1992 and 2002?

Authors:  Cary P Gross; Benjamin D Smith; Elizabeth Wolf; Martin Andersen
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

5.  Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study.

Authors:  L C Harlan; A Potosky; F D Gilliland; R Hoffman; P C Albertsen; A S Hamilton; J W Eley; J L Stanford; R A Stephenson
Journal:  J Natl Cancer Inst       Date:  2001-12-19       Impact factor: 13.506

6.  Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis.

Authors:  Elisabetta Rapiti; Gerald Fioretta; Robin Schaffar; Isabel Neyroud-Caspar; Helena M Verkooijen; Franz Schmidlin; Raymond Miralbell; Roberto Zanetti; Christine Bouchardy
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

7.  Treatment of early-stage prostate cancer among rural and urban patients.

Authors:  Laura-Mae Baldwin; C Holly A Andrilla; Michael P Porter; Roger A Rosenblatt; Shilpen Patel; Mark P Doescher
Journal:  Cancer       Date:  2013-06-13       Impact factor: 6.860

8.  Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study.

Authors:  Richard M Hoffman; William C Hunt; Frank D Gilliland; Robert A Stephenson; Arnold L Potosky
Journal:  Cancer       Date:  2003-04-01       Impact factor: 6.860

9.  Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort.

Authors:  Elyn H Wang; James B Yu; Robert Abouassally; Neal J Meropol; Gregory Cooper; Nilay D Shah; Stephen B Williams; Christopher Gonzalez; Marc C Smaldone; Alexander Kutikov; Hui Zhu; Simon P Kim
Journal:  Urology       Date:  2016-06-16       Impact factor: 2.649

Review 10.  Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Authors:  Timothy J Wilt; Roderick MacDonald; Indulis Rutks; Tatyana A Shamliyan; Brent C Taylor; Robert L Kane
Journal:  Ann Intern Med       Date:  2008-02-04       Impact factor: 25.391

View more
  2 in total

Review 1.  Disparities in the Utilization of Radiation Therapy for Prostate Cancer in the United States: A Comprehensive Review.

Authors:  Ulysses Gardner; Shearwood McClelland; Curtiland Deville
Journal:  Adv Radiat Oncol       Date:  2022-03-18

Review 2.  The Intersection of Rural Residence and Minority Race/Ethnicity in Cancer Disparities in the United States.

Authors:  Whitney E Zahnd; Cathryn Murphy; Marie Knoll; Gabriel A Benavidez; Kelsey R Day; Radhika Ranganathan; Parthenia Luke; Anja Zgodic; Kewei Shi; Melinda A Merrell; Elizabeth L Crouch; Heather M Brandt; Jan M Eberth
Journal:  Int J Environ Res Public Health       Date:  2021-02-03       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.